Translate
Bridgebio Oncology Therapeutics, Inc.
About
Bridgebio Oncology Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Apr 21 2026
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
Apr 20 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Apr 13 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 18 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Recent Videos
23 abril 26. Noticias acciones biotecnológicas. Resumen diario. #trading $XBI #biotechnews
Apr 23, 2026
20 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 21, 2026
Cómo invertir en BridgeBio Oncology Therapeutics Inc (BBOT)
Mar 13, 2026
Why BridgeBio Stopped Galactosemia Gene Therapy
Feb 11, 2026